Key takeaways
Galcanezumab (Emgality) and rimegepant (Nurtec ODT) are both medications used to prevent migraines in adults. However, they belong to different medication classes and have distinct uses and forms. Galcanezumab is a monoclonal antibody that is also used to treat episodic cluster headaches, while rimegepant is a calcitonin gene-related peptide (CGRP) receptor blocker that can also treat migraines with or without aura. Galcanezumab is administered as a subcutaneous injection, typically once a month, whereas rimegepant is taken orally as a dissolvable tablet every other day for prevention or as needed for treatment. Both are only available as brand-name medications. Common side effects of galcanezumab include injection site reactions and sore throat, while rimegepant may cause nausea and stomach pain. Additionally, rimegepant interacts with grapefruit, which can increase the risk of side effects, whereas galcanezumab does not have this interaction.
